Atrial fibrillation is of the most frequently occurred arrhythmia that causes problem with the rhythm of the heart (such as too slow or too fast heart beat). During atrial fibrillation, heart beats are irregular and it can be too slow or too fast as compared to the regular heartbeat. Atrial fibrillation can increase the rate of heart stroke, cause chest pain or even heart attack especially if the heart beat is too fast. During atrial fibrillation, both the chambers (upper and lower) beat irregularly, chaotically, and out of coordination of the heart. Shortness of breath, weakness, chest pain, dizziness, lightheadedness or fainting and heart palpitation are the common symptoms of atrial fibrillation. In addition, atrial fibrillation may lead to formation of blood clots in the heart, which may circulate to other organs. In atrial fibrillation, for altering the electrical system of heart, treatments such as medications and interventions are provided.

Atrial fibrillation market is in its emerging state as the prevalence of atrial fibrillation is growing rapidly along with the increase in aging population. According to American Heart Association, 33.5 million individuals (0.5% of the world's population) were with atrial fibrillation in 2013. Also, technological advancement towards surgical devices for atrial fibrillation fuels the market growth. However, pitfalls such as stringent government policies, high cost of atrial fibrillation treatment, and dearth of skilled professionals and technicians hinders the market growth.

The world atrial fibrillation market has been segmented based on devices and region. Based on devices, the market is segmented into surgical devices and non-surgical devices. Surgical devices are further sub-classified into maze surgery and catheter ablation. Non-surgical devices are further sub-divided into electric cardioversion, diagnostic catheters, mapping and recording systems, cardiac monitors, access devices, left atrial appendage, and closure devices and intracardiac echocardiography (ICE) Systems. The market is analyzed on the basis of four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

The key strategies adopted are product launch, collaboration, and merger & acquisition. For instance, Abbott acquired Kalila Medical, Inc. (U.S.), which helped Abbott develop next generation technologies that are useful to treat cardiac disorders such as atrial fibrillation. Biosense Webster, Inc. acquired Coherex Medical, Inc. (U.S.), which helped Biosense Webster, Inc. to strengthen its medical devices product portfolio.

KEY MARKET BENEFITS:

In-depth analysis of the market is conducted based on market estimations of the key segments for the period 2014-2022
Comprehensive analysis of factors that drive and restrict the growth of the world atrial fibrillation market is provided in the report
Exhaustive analysis of the world atrial fibrillation market by different segments helps understand the different aspects of atrial fibrillation that are currently used along with the variants that would gain prominence in the future
Competitive intelligence of leading manufacturers and distributors of atrial fibrillation market interprets the competitive scenario across various geographies
Key market players within the atrial fibrillation market are profiled in the report and their strategies are analyzed thoroughly, which predicts competitive outlook of the world market.

KEY MARKET SEGMENT:

By Devices

Surgical Devices
Maze Surgery
Catheter Ablation
Radiofrequency Catheter Ablation
Conventional RF Ablation Catheters
Irrigated-tip RF Ablation Catheters
Cryoablation
Microwave Based Catheter Ablation
Laser Based Catheter Ablation
Navigational Advanced Mapping Accessories
Non-Surgical Devices
Electric Cardioversion
Diagnostic Catheters
Conventional Diagnostic Catheters
Fixed Diagnostic Catheters
Steerable Diagnostic Catheters
Advanced Diagnostic Catheters
Mapping and Recording Systems
Cardiac Monitors
Access Devices
Left Atrial Appendage and Closure Devices
Intracardiac Echocardiography (ICE) Systems

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
India
China
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Egypt
Israel
South Africa
Rest of LAMEA

KEY PLAYERS

Abbott Laboratories
Johnson & Johnson
MicroPort Scientific Corporation
Boston Scientific Corporation
St. Jude Medical, Inc.
Medtronic plc
Biotronik SE & Co. KG
Koninklijke Philips N.V.
Siemens AG
AtriCure Inc.

Other players in the value chain include

Biosense Webster, Inc.
CardioFocus, Inc.
CathEffects Inc.
CathRx Ltd.
EndoPhotonix, Inc.
Japan Lifeline Co.
Osypka AG
Pioneer Medical Devices AG
GE Healthcare
TZ Medical, Inc.

*Profiles of these players are not included. The same will be included on request.